Is Insulet Corporation (PODD) Overvalued?
We dive into why Insulet Corporation (PODD) could be considered overvalued on 2026-07-23, based on AAII’s Value Score and Grade.Jenna Brashear
Stock Evaluator: Insulet Corporation (PODD)
Insulet Corporation PODD
$165.35
-0.33
-0.20%
July 31, 2026 4:00:00 PM
EST
Volume: 1,313,891
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Commentary & Analysis
Why Insulet Corporation’s (PODD) Stock Is Down 5.28%
As of Monday, July 06, Insulet Corporation’s PODD share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Which Is a Better Investment, NovoCure Limited or Insulet Corporation Stock?
Learn more about whether NovoCure Limited or Insulet Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, Axogen, Inc. or Insulet Corporation Stock?
Learn more about whether Axogen, Inc. or Insulet Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Glaukos Corporation or Insulet Corporation Stock?
Learn more about whether Glaukos Corporation or Insulet Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | PODD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11,477.8 | $334.8 | 79% |
|
| Shares Out (Mil) | 70.2 | 41.7 | 56% |
|
| Institutional Ownership | 99.7% | 77.3% | 93% |
|
| Float (Mil) | 69.0 | 34.7 | 54% |
|
| Beta | 1.12 | 0.86 | 66% |
|
| Avg Daily Volume (000s) | 1,261 | 266 | 75% |
|
| Price Change (52-week) |
(43.2%) | 60.7% | 18% |
|
| Growth | PODD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.5% | 11.8% | 86% |
|
| Net Income (5yr) | 105.2% | (5.8%) | 99% |
|
| EPS (5yr) | 103.4% | 10.7% | 99 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.2%) | (16.1%) | 38% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 22 | 23 | 23 | |
| Current EPS | $1.453 | $6.482 | $8.054 | |
| Month Ago EPS | $1.450 | $6.481 | $8.084 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | $1.439 | $6.347 | $8.071 | |
| Year/Year Chg | 11.8% | 86.3% | 190.7% | |
| Financials | PODD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,901 | $152 | 66% |
|
| Net Income (TTM) (Mil) | $303 | ($11) | 73% |
|
| EPS (TTM) | $4.309 | ($0.500) | 85% |
|
| Operating Cash Flow (TTM) (Mil) | $619 | ($2) | 74% |
|
| Net Cash Flow (TTM) (Mil) | ($803) | $1 | 4% |
|
| Long-Term Debt (Q1) (Mil) | $995 | $22 | 66% |
|
| Enterprise Value (Q1) (Mil) | $11,495 | $304 | 76% |
|
| Valuation | PODD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.81 | 2.88 | 88% |
|
| P/E | 38.6 | 30.5 | 77% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.4 | 1.9 | 17% |
|
| Ratios | PODD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 71.0% | 59.1% | 82% |
|
| Net Margin | 10.4% | (7.7%) | 64% |
|
| ROA | 9.3% | (13.7%) | 86% |
|
| ROE | 23.0% | (15.9%) | 83% |
|
| Liabilities to Assets | 56.4% | 44.9% | 49% |
|
| F-Score | 7 | 4 | 84% |
|
Insulet Corporation did not pass any screens on 7/30/2026.
